Methods for assessing and removing non‐specific photoimmunotherapy damage in patient‐derived tumor cell culture models

Abstract

AbstractTumor‐targeted, activatable photoimmunotherapy (taPIT) has been shown to selectively destroy tumor in a metastatic mouse model. However, the photoimmunoconjugate (PIC) used for taPIT includes a small fraction of non‐covalently associated (free) benzoporphyrin derivative (BPD), which leads to non‐specific killing in vitro. Here, we report a new treatment protocol for patient‐derived primary tumor cell cultures ultrasensitive to BPD photodynamic therapy (BPD‐PDT). Based on free BPD efflux dynamics, the updated in vitro taPIT protocol precludes non‐specific BPD‐PDT by silencing the effect of free BPD. Following incubation with PIC, incubating cells with PIC‐free medium allows time for expulsion of free BPD whereas BPD covalently bound to PIC fragments is retained. Administration of the light dose after the intracellular free BPD drops below the threshold for inducing cell death helps to mitigate non‐specific damage. In this study, we tested two primary ovarian tumor cell lines that are intrinsically chemoresistant, yet ultrasensitive to BPD‐PDT such that small amounts of free BPD (a few percent of the total BPD dose) lead to potent induction of cell death upon irradiation. The modifications in the protocol suggested here improve in vitro taPIT experiments that lack in vivo mechanisms of free BPD clearance (i.e., lymph and blood flow).